Gefitinib-Tamoxifen Hybrid Ligands as Potent Agents against Triple-Negative Breast Cancer
出版年份 2022 全文链接
标题
Gefitinib-Tamoxifen Hybrid Ligands as Potent Agents against Triple-Negative Breast Cancer
作者
关键词
-
出版物
JOURNAL OF MEDICINAL CHEMISTRY
Volume 65, Issue 6, Pages 4616-4632
出版商
American Chemical Society (ACS)
发表日期
2022-03-15
DOI
10.1021/acs.jmedchem.1c01646
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors
- (2020) Amr K.A. Bass et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen
- (2019) A.B. Sanchez-Spitman et al. Expert Review of Clinical Pharmacology
- Molecular Hybridization as a Tool for Designing Multitarget Drug Candidates for Complex Diseases
- (2019) Viktoriya Ivasiv et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Pharmacological, Mechanistic, and Pharmacokinetic Assessment of Novel Melatonin-Tamoxifen Drug Conjugates as Breast Cancer Drugs
- (2019) Mahmud Hasan et al. MOLECULAR PHARMACOLOGY
- Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - a new hybrid design paradigm
- (2018) Anthony F. Palermo et al. BIOORGANIC & MEDICINAL CHEMISTRY
- A multi-gram-scale stereoselective synthesis of Z -endoxifen
- (2018) Lech-Gustav Milroy et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- New Class of Selective Estrogen Receptor Degraders (SERDs): Expanding the Toolbox of PROTAC Degrons
- (2018) Lucia Wang et al. ACS Medicinal Chemistry Letters
- Recent advances (2015–2016) in anticancer hybrids
- (2017) Nagaraju Kerru et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Protein Kinase Targets in Breast Cancer
- (2017) Marilina García-Aranda et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site
- (2017) Marcel Günther et al. JOURNAL OF MEDICINAL CHEMISTRY
- AMPK Activation and Metabolic Reprogramming by Tamoxifen through Estrogen Receptor-Independent Mechanisms Suggests New Uses for This Therapeutic Modality in Cancer Treatment
- (2016) N. A. Daurio et al. CANCER RESEARCH
- Novel Selective and Potent EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer
- (2016) Yanxia Li et al. MOLECULES
- Antibody-drug conjugates: recent advances in conjugation and linker chemistries
- (2016) Kyoji Tsuchikama et al. Protein & Cell
- Synthesis and evaluation of tamoxifen derivatives with a long alkyl side chain as selective estrogen receptor down-regulators
- (2015) Takuji Shoda et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Mechanisms of Gefitinib-mediated reversal of tamoxifen resistance in MCF-7 breast cancer cells by inducing ERα re-expression
- (2015) Xia Zhang et al. Scientific Reports
- Design and synthesis of tamoxifen derivatives as a selective estrogen receptor down-regulator
- (2013) Takuji Shoda et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Advances in the development of hybrid anticancer drugs
- (2013) Sébastien Fortin et al. Expert Opinion on Drug Discovery
- Histone Deacetylase Inhibitors Equipped with Estrogen Receptor Modulation Activity
- (2013) Berkley E. Gryder et al. JOURNAL OF MEDICINAL CHEMISTRY
- Activity-based kinase profiling of approved tyrosine kinase inhibitors
- (2012) Daisuke Kitagawa et al. GENES TO CELLS
- Newin VitroTools to Study Human Constitutive Androstane Receptor (CAR) Biology: Discovery and Comparison of Human CAR Inverse Agonists
- (2011) Jenni Küblbeck et al. MOLECULAR PHARMACEUTICS
- Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity
- (2011) Theonie Anastassiadis et al. NATURE BIOTECHNOLOGY
- The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway
- (2011) K. Jin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer
- (2010) Xiong Cai et al. JOURNAL OF MEDICINAL CHEMISTRY
- Triple-Negative Breast Cancer
- (2010) William D. Foulkes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tamoxifen Inhibits TRPV6 Activity via Estrogen Receptor-Independent Pathways in TRPV6-Expressing MCF-7 Breast Cancer Cells
- (2009) K. A. Bolanz et al. MOLECULAR CANCER RESEARCH
- Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic Function
- (2008) S. Massarweh et al. CANCER RESEARCH
- Synthesis and Evaluation of Estrogen Agonism of Diaryl 4,5-Dihydroisoxazoles, 3-Hydroxyketones, 3-Methoxyketones, and 1,3-Diketones: A Compound Set Forming a 4D Molecular Library
- (2008) Juha T. Pulkkinen et al. JOURNAL OF MEDICINAL CHEMISTRY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started